EC Number   |
Disease |
PubMed ID |
Title of Publication |
Category |
Confidence Level |
|---|
   3.4.22.68 | Adenocarcinoma |
25217324 |
SUMO-specific protease 1 regulates pancreatic cancer cell proliferation and invasion by targeting MMP-9. |
causal interaction
diagnostic usage
ongoing research
unassigned |
4
2
2
0 |
| 3.4.22.68 | Altitude Sickness |
25225945 |
Genetic variation in SENP1 and ANP32D as predictors of chronic mountain sickness. |
causal interaction
diagnostic usage
unassigned |
2
2
0 |
| 3.4.22.68 | Altitude Sickness |
26952840 |
SENP1, but not fetal hemoglobin, differentiates Andean highlanders with chronic mountain sickness from healthy individuals among Andean highlanders. |
diagnostic usage
unassigned |
1
0 |
| 3.4.22.68 | Anemia |
17981124 |
SUMO-specific protease 1 is essential for stabilization of HIF1alpha during hypoxia. |
ongoing research
therapeutic application
unassigned |
3
1
0 |
| 3.4.22.68 | Anemia |
20457756 |
SENP1-mediated GATA1 deSUMOylation is critical for definitive erythropoiesis. |
unassigned |
0 |
| 3.4.22.68 | Arthritis, Rheumatoid |
20079608 |
Epigenetics and rheumatoid arthritis: The role of SENP1 in the regulation of MMP-1 expression. |
ongoing research
unassigned |
2
0 |
| 3.4.22.68 | Astrocytoma |
27693211 |
Inhibition of SUMO-specific protease 1 induces apoptosis of astroglioma cells by regulating NF-?B/Akt pathways. |
causal interaction
diagnostic usage
ongoing research
therapeutic application |
4
4
4
4 |
| 3.4.22.68 | Ataxia Telangiectasia |
21777808 |
NF-?B Induction of the SUMO Protease SENP2: A Negative Feedback Loop to Attenuate Cell Survival Response to Genotoxic Stress. |
therapeutic application
unassigned |
1
0 |
| 3.4.22.68 | Atherosclerosis |
25689261 |
Disturbed flow-activated p90RSK kinase accelerates atherosclerosis by inhibiting SENP2 function. |
therapeutic application
unassigned |
1
0 |
| 3.4.22.68 | Atherosclerosis |
29969578 |
SUMO-specific protease 2 (SENP2) suppresses keratinocyte migration by targeting NDR1 for de-SUMOylation. |
unassigned |
0 |
